Evidence map›Paper›PMID 32225110›Full record

ArticleInternational journal of molecular sciences2020

Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression.

Hitomi Sudo, Atsushi B Tsuji, Aya Sugyo, Gene Kurosawa, Yoshikazu Kurosawa, David Alexander, Hiroyuki Tsuda, Tsuneo Saga, Tatsuya Higashi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. CD73: Friend or Foe in Lung Injury.International journal of molecular sciences · 2023
    Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hitomi SudoDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Inage, Chiba 263-8555, Japan.
Atsushi B TsujiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Inage, Chiba 263-8555, Japan.ORCID 0000-0003-2726-288X
Aya SugyoDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Inage, Chiba 263-8555, Japan.
Gene KurosawaInternational Center for Cell and Gene Therapy, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.
Yoshikazu KurosawaDepartment of Innovation Center for Advanced Medicine, Research Promotion Support Center, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.
David AlexanderNanotoxicology Project, Nagoya City University, 3-1 Tanabe-dohri, Mizuho-ku, Nagoya 466-8603, Japan.
Hiroyuki TsudaNanotoxicology Project, Nagoya City University, 3-1 Tanabe-dohri, Mizuho-ku, Nagoya 466-8603, Japan.
Tsuneo SagaDepartment of Advanced Medical Imaging Research, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology (QST-NIRS), Inage, Chiba 263-8555, Japan.
National Institutes for Quantum Science and Technology · JPFujita Health University Hospital · JPNagoya City University · JPKyoto University · JP

Funding

Japan Society for the Promotion of Science KAKENHI17K10497Japan Society for the Promotion of Science KAKENHI18H02774Japan Society for the Promotion of Science KAKENHI18K07778Princess Takamatsu Cancer Research Fund 17-24907
6 · The paper itself

Abstract

backgroundCD73 is an ectonucleotidase regulating extracellular adenosine concentration and plays an important role in adenosine-mediated immunosuppressive pathways. The efficacy of CD73-targeted therapy depends on the expression levels of CD73; therefore, monitoring CD73 status in cancer patients would provide helpful information for selection of patients who would benefit from CD73-targeted therapy. Here, we evaluated the ability of

methodsCell binding and competitive inhibition assays for

results

conclusions

Indexed as

5'-NucleotidaseAnimalsAntibodies, MonoclonalCell Line, TumorFemaleHumansIndium RadioisotopesMiceMice, Inbred BALB CMice, NudeRadiopharmaceuticalsRatsRats, Sprague-DawleySingle Photon Emission Computed Tomography Computed TomographyTissue Distribution5'-NucleotidaseAntibodies, MonoclonalIndium RadioisotopesRadiopharmaceuticalsCD73EctonucleotidaseExtracellular adenosineImmune checkpointNuclear Medicine imagingStratification of patientsTumor microenvironment

Identifiers

PMID32225110
PMCPMC7177856
OpenAlexW3013050939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.